Evidence map›Paper›PMID 36149525›Full record

ArticleCerebellum (London, England)2023

Noradrenergic Pathway to the Cerebellum: the Study Must Go On.

Shigeki Hirano, Atsuhiko Sugiyama, Kimihito Arai

Abstract read
PubMed Publisher
In one paragraph

Article in Cerebellum (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Shigeki HiranoDepartment of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan. s_hirano@chiba-u.jp.
Atsuhiko SugiyamaDepartment of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Kimihito AraiDepartment of Neurology, National Hospital Organization Chibahigashi National Hospital, Chiba, Japan.
Chiba University · JPNational Hospital Organization · JPNational Institutes for Quantum and Radiological Science and Technology · JP

Funding

Japan Society for the Promotion of Science 18K07543
6 · The paper itself

Abstract

In 1967, Andén, Fuxe, and Ungerstedt demonstrated the presence of monoamine-containing fibers in the rat cerebellum. Over the past 50 years, this finding has provided clinical relevance of the noradrenergic system to the cerebellum. Cerebellar dysfunction and noradrenergic system may relate to tremor in Parkinson disease and essential tremor, motor learning, and the vestibulo-ocular reflex in spinocerebellar ataxias. Cognition and emotion may also be linked to the cerebellar noradrenergic system, in relation to the symptoms of Alzheimer disease, dementia with Lewy bodies, and attention-deficit/hyperactivity disorder. Despite recent technological advances in neuroimaging for evaluating the noradrenergic system, we need more evidence to understand the precise pathophysiological relationship between the cerebellum and the noradrenergic system and its clinical implications.

Indexed as

Cerebellar DiseasesParkinson DiseaseAnimalsCerebellumNorepinephrineRatsTremorNorepinephrineCerebellumLocus coeruleusNoradrenaline

Identifiers

PMID36149525
OpenAlexW4296699794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.